source
- Ultragenyx's Angelman gene therapy fails Phase 3, company to cut expensesUltragenyx reported that its late‑stage Aspire trial of apazunersen in Angelman syndrome did not meet its primary or secondary endpoints. The primary goal of improving the Bayley‑4 cognitive raw sc…
- Merck's dealmaker warns of increased M&A activity as Keytruda patent expiresMerck's chief M&A officer says the company expects a surge in deal flow as the patent for its flagship immunotherapy, Keytruda, approaches expiration. The leadership has been pursuing acquisitions…